China Biopharmaceutical Industry Report, 2007-2008
  • Dec/2007
  • Hard Copy
  • USD $1,900
  • Pages:95
  • Single User License
    (PDF Unprintable)       
  • USD $2,000
  • Code: FB001
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,100
      

Pharmaceutical industry is a sunrise industry, especially the biopharmaceuticals, which just starts its large-scale industrialization process. Many large biotech and pharmaceutical companies are strengthening their presence worldwide. Compared with traditional pharmaceutical industry, biopharmaceutical industry sees a higher market concentration, and this is more helpful for strong enterprises to grow stronger and for building a number of leading enterprises in the segment areas. Currently, traditional chemical pharmaceutical makers also start turning their eyes towards biopharmaceutical field, and keep themselves busy in establishing much more strategic alliance.

China's pharmaceutical industry has been growing at 20% on the average in production value over the past decade, nearly doubled every four years. In Jan-Jul 2007, the accumulated production value of the entire industry reached RMB 342.449 billion, up 23.47% compared to the same period of last year, of which, production value of bio-pharmaceuticals was RMB 30.229 billion, up 24.37% from a year earlier.

Total Industrial Output Value and Growth, Jan-Jul 2007

 
 
Source: State Information Center

China's biopharmaceutical industry could not only produce internationally important biologic drugs, but develop independently new biological drugs. Furthermore, China has achieved great breakthrough in gene engineering, biopharmaceuticals and clone technology. Despite of the rapid growth, there are still serious problems in China's biopharmaceutical industry:

China is weak in the investment, R&D capability and technology innovation;
There are serious repeated construction problems in drug development and production;
Overall, enterprises are small-sized, and with low modernization level and outmoded equipments;
Marketing strategies are unreasonable, mainly in brand development;
Management is outdated and talents capable of both technology and operation fall short;
 There are no enough exchange and cooperation among enterprises.

Biopharmaceutical industry includes four segment markets: gene engineering, bacterin, blood products and diagnostic reagent. After more than a decade of development, these four segment markets find many aggressive private or state-owned biopharmaceutical enterprises through which China is to fulfill its supports to the whole industry. As far as capital market is concerned, as concept investment bubble fades away, Chinese pharmaceutical enterprises are expected to be gradually accepted by the market with its high growth potentials.

Polices have a great influence on China's biopharmaceutical industry, so how many efforts China will make to support the industry plays a significant role in its development. In fact, China always keeps a close eye on biopharmaceutical industry and has frequently issued related policies in recent two years, which is very positive for stimulating the development of biopharmaceutical industry and for regulating industry rules, and also brings energy and opportunities into the biopharmaceutical industry.

Related Laws and Regulations Issued in 2007

 
 

Based on the study on China pharmaceutical industry's status quo, competitive pattern, investment and developing trend, this report puts its emphasis on output and sales situation of main drugs, impact China's pharmaceutical industry will face as well as strategies enterprises should make.

1 Operation Status of China Pharmaceutical Industry in 2007
1.1 Overview
1.2 Problems in China pharmaceutical market
1.2.1 Competition in production is rampant
1.2.2 Capability in innovation is poor
1.2.3 Drug quality appears thread-and-thrum
1.2.4 Financing channel is undiversified and investment is in short
1.2.5 Drug circulation market is unorderly
1.3 Policies adjustment in China's pharmaceutical industry in 2007

2 Overview of Biopharmaceutical Industry
2.1 Brief introduction to biopharmaceutical industry
2.1.1 Definition
2.1.2 Development history
2.2 Main products and characteristics of biopharmaceutical industry
2.2.1 Main products
2.2.2 Characteristics
2.3 Development status of global pharmaceutical industry
2.3.1 USA
2.3.2 Europe
2.3.3 Japan
2.3.4 India

3 Environments in China Biopharmaceutical Industry
3.1 Macro environments
3.1.1 General situation of macroeconomic in China, 2007
3.1.2 Economic operations of China pharmaceutical industry
3.1.3 Influences caused by variational macro environments in China medical treatment field
3.2 Policy environments
3.2.1 Drug registration
3.2.2 Drug production
3.3.3 Drug circulation
3.3.4 Drug application
3.2.5 Supervision on sub-industries

4 Status Quo of China Biopharmaceutical Industry
4.1 Operations
4.2 Production technology
4.3 Major problems
4.3.1 Enterprises operate mostly at a small size
4.3.2 Repeated construction problems are serious
4.3.3 R&D capability is weak
4.3.4 Industry concentration is at a low level
4.3.5 Basic R&D results are unable to be converted efficiently

5 Industrial Systems in China Biopharmaceutical Industry
5.1 Biopharmaceutical industry systems
5.2 Problems exist in China biopharmaceutical industry systems
5.3 Value chain analysis in biopharmaceutical industry

6 Main biopharmaceutical products
6.1 Blood products
6.1.1 Operations status
6.1.2 Main blood products
6.1.3 Competitiveness
6.2 Bacterin
6.2.1 Overview of Bacterin market
6.2.2 Polices on immunity plan promote bacterin market to grow fast
6.2.3 Market competitiveness
6.2.4 Segment markets

7 Listed Companies
7.1 Hualan Biological Engineering Inc.
7.1.1 Company Profile
7.1.2 Operations in 2007
7.1.3 Opportunities and risks
7.2 Shanghai Kehua Bio-engineering Co., Ltd
7.2.1 Company profile
7.2.2 Operations in 2007
7.2.3 Risks
7.3 Beijing Tiantan Biological Products Co., Ltd
7.3.1 Company profile
7.3.2 Operations in 2007
7.3.3 Opportunities and risks
7.4 Da An Gene Co., Ltd of Sun Yat-Sen University
7.4.1 Company profile
7.4.2 Operations in 2007
7.4.3 Opportunities and risks

8 Foreign Companies in China
8.1 Bayer
8.1.1 Operations in China
8.1.2 Investments in China
8.2 AstraZeneca
8.3 Pfizer
8.3.1 Operations in China
8.3.2 Investments in China
8.4 Sanofipasteur
8.5 Novartis
8.6 GlaxoSmithKline (GSK)
8.7 Lilly
8.8 Co-operative Group
Revenue and Profit Growth of Pharmaceutical Industry by Segment, Jan-Aug 2007
Growth of Sales Revenue and Gross Profit of Pharmaceutical Industry
Per Capita GDP and Medical Care Depending/GDP Worldwide
Forecast on Trend of Proportion of Total Health Expenditure to GDP in China
Total Sum Spent by Sample Hospitals on Albumin Market
Ranking of Drugs Used by Hospitals by Purchase Sum, 2006
Price Trend of Albumin
Product Structure of Blood Products Market in China, 2006
Product Structure of Blood Products Market in the World, 2006
PCC Market Share by Manufacturer, 2006
IVIG Market Share by Manufacturer, 2006
HRIG Market Share by Manufacturer, 2006
List of Blood Products Manufacturers in China
Total Amount of Plasma in China
Product Structure of Key Blood Products Manufacturers
Share of Sample Hospitals in Albumin Market, 2006
Main Brands of Imported Human Serum Albumin Injections in China
Newly-increased Bacterins after Starting the Expanded Program on Immunization
Number of Manufacturers by Main Bacterin
Key Projects in Process
Main Business Revenue and Gross Profit Margin by Company
Profitability Indices by Company
Indices of Operating Ability and Debt-Paying Ability by Company
Product Structure Change by Company
Shareholding Structure of Da An Gene Co., Ltd of Sun Yat-Sen University
Financial Indices of Listed Diagnostic Reagents Companies, 2007H1
Forecast on Da An Gene's Diagnostic Reagents Development
Key PCR Reagents Manufacturers in China
Comparison of In-Vitro Diagnostic Methods
Catalog of PCR Reagents Reported by Da An Gene to State Food and Drug Administration, 2006-2007
Penetration Status of Medical Insurance System
Population and Structure in China
Engel's Coefficient Change in China
Per Capita Health Expenditure in China, 2000-2004
Major Laws and Regulations Issued in 2007
Market Capacity of Segmented Blood Products
Supervision Policies on Blood Products

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号